GeneDx Holdings Corp. (NASDAQ: WGS) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
GeneDx Holdings Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $47.29, GeneDx Holdings Corp. trades at 3.1x sales and 5.8x book value. Over the last twelve months it generated about $462M of revenue and a net loss of $114M. It runs a gross margin of 67.6%, an operating margin of -14.7% and a net margin of -24.1%. It shows return on equity of -42.3%, return on invested capital of -14.7% and a free cash flow yield of -7.1%. On the balance sheet: a debt-to-equity ratio of 0.88 and a current ratio of 4.16. Over the past 52 weeks the share price ranged from $32.21 to $170.87, with a beta of 1.99.
GeneDx Holdings Corp. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.